Cargando…

F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis

BACKGROUND: Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC). PURPOSE: To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy. MATER...

Descripción completa

Detalles Bibliográficos
Autores principales: Haslerud, Torjan, Brauckhoff, Katrin, Reisæter, Lars, Küfner Lein, Regina, Heinecke, Achim, Varhaug, Jan Erik, Biermann, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015757/
https://www.ncbi.nlm.nih.gov/pubmed/26163534
http://dx.doi.org/10.1177/0284185115594645
_version_ 1782452482923823104
author Haslerud, Torjan
Brauckhoff, Katrin
Reisæter, Lars
Küfner Lein, Regina
Heinecke, Achim
Varhaug, Jan Erik
Biermann, Martin
author_facet Haslerud, Torjan
Brauckhoff, Katrin
Reisæter, Lars
Küfner Lein, Regina
Heinecke, Achim
Varhaug, Jan Erik
Biermann, Martin
author_sort Haslerud, Torjan
collection PubMed
description BACKGROUND: Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC). PURPOSE: To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy. MATERIAL AND METHODS: A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance measures were pooled using Reitsma’s bivariate model. RESULTS: Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity were 79.4% (95% confidence interval [CI], 73.9–84.1) and 79.4% (95% CI, 71.2–85.4), respectively, with an area under the curve of 0.858. CONCLUSION: F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative therapy.
format Online
Article
Text
id pubmed-5015757
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-50157572016-09-12 F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis Haslerud, Torjan Brauckhoff, Katrin Reisæter, Lars Küfner Lein, Regina Heinecke, Achim Varhaug, Jan Erik Biermann, Martin Acta Radiol Head and Neck BACKGROUND: Positron emission tomography (PET) with fluor-18-deoxy-glucose (FDG) is widely used for diagnosing recurrent or metastatic disease in patients with differentiated thyroid cancer (DTC). PURPOSE: To assess the diagnostic accuracy of FDG-PET for DTC in patients after ablative therapy. MATERIAL AND METHODS: A systematic search was conducted in Medline/PubMed, EMBASE, Cochrane Library, Web of Science, and Open Grey looking for all English-language original articles on the performance of FDG-PET in series of at least 20 patients with DTC having undergone ablative therapy including total thyroidectomy. Diagnostic performance measures were pooled using Reitsma’s bivariate model. RESULTS: Thirty-four publications between 1996 and 2014 met the inclusion criteria. Pooled sensitivity and specificity were 79.4% (95% confidence interval [CI], 73.9–84.1) and 79.4% (95% CI, 71.2–85.4), respectively, with an area under the curve of 0.858. CONCLUSION: F18-FDG-PET is a useful method for detecting recurrent DTC in patients having undergone ablative therapy. SAGE Publications 2015-07-09 2016-10 /pmc/articles/PMC5015757/ /pubmed/26163534 http://dx.doi.org/10.1177/0284185115594645 Text en © The Foundation Acta Radiologica 2015 http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Head and Neck
Haslerud, Torjan
Brauckhoff, Katrin
Reisæter, Lars
Küfner Lein, Regina
Heinecke, Achim
Varhaug, Jan Erik
Biermann, Martin
F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
title F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
title_full F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
title_fullStr F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
title_full_unstemmed F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
title_short F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis
title_sort f18-fdg-pet for recurrent differentiated thyroid cancer: a systematic meta-analysis
topic Head and Neck
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015757/
https://www.ncbi.nlm.nih.gov/pubmed/26163534
http://dx.doi.org/10.1177/0284185115594645
work_keys_str_mv AT haslerudtorjan f18fdgpetforrecurrentdifferentiatedthyroidcancerasystematicmetaanalysis
AT brauckhoffkatrin f18fdgpetforrecurrentdifferentiatedthyroidcancerasystematicmetaanalysis
AT reisæterlars f18fdgpetforrecurrentdifferentiatedthyroidcancerasystematicmetaanalysis
AT kufnerleinregina f18fdgpetforrecurrentdifferentiatedthyroidcancerasystematicmetaanalysis
AT heineckeachim f18fdgpetforrecurrentdifferentiatedthyroidcancerasystematicmetaanalysis
AT varhaugjanerik f18fdgpetforrecurrentdifferentiatedthyroidcancerasystematicmetaanalysis
AT biermannmartin f18fdgpetforrecurrentdifferentiatedthyroidcancerasystematicmetaanalysis